Analyze Diet

Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma.

Abstract: A sensitive reversed-phase HPLC-UV method was developed for the determination of firocoxib, a novel and highly selective COX-2 inhibitor, in plasma. A 1.0 mL dog or horse plasma sample is mixed with water and passed through a hydrophobic-lipophilic copolymer solid-phase extraction column to isolate firocoxib. Quantitation is based on an external standard curve. The method has a validated limit of quantitation of 25 ng/mL and a limit of detection of 10 ng/mL. The validated upper limit of quantitation was 2500 ng/mL for horses and 10,000 ng/mL for dogs. The average recoveries ranged from 88-93% for horse plasma and 96-103% for dog plasma. The coefficient of variation in all cases was less than 10%. This method is suitable for the analysis of clinical samples from pharmacokinetic and bioequivalence studies and drug monitoring.
Publication Date: 2007-05-10 PubMed ID: 17537684DOI: 10.1016/j.jchromb.2007.04.037Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Validation Study

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article summarises the development of a sensitive high-performance liquid chromatography-ultraviolet (HPLC-UV) method to measure levels of firocoxib, a selective COX-2 inhibitor, in horse and dog plasma.

Methodology

  • The researchers developed a reversed-phase HPLC-UV method to determine the quantity of firocoxib, a specific COX-2 inhibitor, in plasma samples.
  • This method starts by mixing a 1.0 mL sample of dog or horse plasma with water. This mixture is then passed through a hydrophobic-lipophilic copolymer solid-phase extraction column, which helps in isolating firocoxib from the other components present in the plasma.
  • Quantitation of firocoxib is determined by comparing to an external standard curve.

Validation and Results

  • The method developed was validated and it showed to have a limit of quantitation of 25 ng/mL and a detection limit of 10 ng/mL. These parameters define the smallest amount of firocoxib that can be measured quantitatively and detected, respectively.
  • The validated upper limit of quantitation, representing the largest quantity of firocoxib that could be accurately measured using this method, was found to be 2500 ng/mL for horses and 10,000 ng/mL for dogs.
  • The average recoveries of firocoxib from the plasma samples were high, ranging from 88-93% for horse plasma and 96-103% for dog plasma, indicating that the method is efficient in extracting and determining firocoxib.
  • The coefficient of variation for all measurements was less than 10%, suggesting that the method provides consistent results.

Conclusion

  • Given the validation results, the HPLC-UV method developed for the determination of firocoxib in plasma samples is thought to be suitable for analyzing clinical samples from pharmacokinetic and bioequivalence studies and drug monitoring.
  • This allows for better understanding of firocoxib behaviour within the body, its pharmacokinetics, and can also aid in monitoring the drug levels in dogs and horses, making it a valuable tool in veterinary medicine.

Cite This Article

APA
Kvaternick V, Malinski T, Wortmann J, Fischer J. (2007). Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 854(1-2), 313-319. https://doi.org/10.1016/j.jchromb.2007.04.037

Publication

ISSN: 1570-0232
NlmUniqueID: 101139554
Country: Netherlands
Language: English
Volume: 854
Issue: 1-2
Pages: 313-319

Researcher Affiliations

Kvaternick, Valerie
  • Merial Limited, Pharmacokinetics and Drug Metabolism, 631 Route 1, North Brunswick, NJ 08902, USA. valerie.kvaternick@merial.com
Malinski, Thomas
    Wortmann, Jill
      Fischer, James

        MeSH Terms

        • 4-Butyrolactone / analogs & derivatives
        • 4-Butyrolactone / blood
        • 4-Butyrolactone / pharmacokinetics
        • Animals
        • Anti-Inflammatory Agents, Non-Steroidal / blood
        • Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
        • Chromatography, High Pressure Liquid / methods
        • Dogs
        • Horses
        • Reference Standards
        • Reproducibility of Results
        • Sensitivity and Specificity
        • Spectrophotometry, Ultraviolet / methods
        • Sulfones / blood
        • Sulfones / pharmacokinetics
        • Therapeutic Equivalency

        Citations

        This article has been cited 5 times.
        1. Brandi A, de Faria Lainetti P, Elias F, Rodrigues MMP, Fagundes Moraes L, Laufer-Amorim R, de Camargo LS, Salles Gomes COM, Fonseca-Alves CE. Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors. Animals (Basel) 2022 Dec 23;13(1).
          doi: 10.3390/ani13010060pubmed: 36611669google scholar: lookup
        2. Donnell JR, Frisbie DD. Use of firocoxib for the treatment of equine osteoarthritis. Vet Med (Auckl) 2014;5:159-168.
          doi: 10.2147/VMRR.S70207pubmed: 32670856google scholar: lookup
        3. Barton MH, Paske E, Norton N, King D, Giguère S, Budsberg S. Efficacy of cyclo-oxygenase inhibition by two commercially available firocoxib products in horses. Equine Vet J 2014 Jan;46(1):72-5.
          doi: 10.1111/evj.12095pubmed: 23662599google scholar: lookup
        4. Shapiro AJ, Kimble B, Hulst F, Herrin KV, Marschner C, Chen CJ, Govendir M. Pharmacokinetic profile of oral firocoxib in the koala (Phascolarctos cinereus). PLoS One 2025;20(9):e0332448.
          doi: 10.1371/journal.pone.0332448pubmed: 41026701google scholar: lookup
        5. Gumułka P, Pecio Ł, Żmudzki P, Ciura K, Skalicka-Woźniak K, Dąbrowska M, Starek M. Comprehensive Assessment of the Stability of Selected Coxibs in Variable Environmental Conditions along with the Assessment of Their Potential Hepatotoxicity. Pharmaceutics 2023 Nov 9;15(11).
          doi: 10.3390/pharmaceutics15112609pubmed: 38004587google scholar: lookup